Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer.

To assess the prophylactic efficacy of postoperative single intravesical instillation with pirarubicin (THP) and mitomycin C (MMC) for low-risk non-muscle-invasive bladder cancer (NMBC).

A total of 103 clinically low-risk NMBC patients were preoperatively randomized into either THP (n=49) or MMC (n=54) groups. The primary endpoint was recurrence-free survival.

The median follow-up periods of the THP and MMC groups were 955 and 1008 days, respectively (p=0.76). Twelve patients (24.5%) in the THP group and 7 (13%) in the MMC group had bladder cancer recurrences. The two-year recurrence-free survival of the THP group and the MMC group was 77.8% and 86.4%, respectively (p=0.20). Neither groups had severe toxicity.

In low-risk NMBC, the prophylactic effect against postoperative single intravesical instillation with THP was not superior to that with MMC.

Anticancer research. 2020 Sep [Epub]

Shinya Yamamoto, Yukio Kageyama, Yasuhisa Fujii, Taku Aizawa, Shinji Urakami, Iwao Fukui

Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan ., Department of Urology, Saitama Cancer Center, Saitama, Japan., Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Department of Urology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.